PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Chemotherapy and Pharmacology10.1007/s00280-017-3411-92017804729-735Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and reviewJung Han Kim, Bum Jun Kim, Hyun Joo Jang, Hyeong Su Kimhttp://link.springer.com/article/10.1007/s00280-017-3411-9/fulltext.html, http://link.springer.com/content/pdf/10.1007/s00280-017-3411-9.pdf, http://link.springer.com/content/pdf/10.1007/s00280-017-3411-9.pdf
Nuclear Medicine and Molecular Imaging10.1007/s13139-018-0548-32018526420-429Evaluation of RECIST, PERCIST, EORTC, and MDA Criteria for Assessing Treatment Response with Ga68-PSMA PET-CT in Metastatic Prostate Cancer Patient with Biochemical Progression: a Comparative StudyManoj Gupta, Partha Sarathi Choudhury, Sudhir Rawal, Harish Chandra Goel, S. Avinash Raohttp://link.springer.com/article/10.1007/s13139-018-0548-3/fulltext.html, http://link.springer.com/content/pdf/10.1007/s13139-018-0548-3.pdf, http://link.springer.com/content/pdf/10.1007/s13139-018-0548-3.pdf
European Journal of Nuclear Medicine and Molecular Imaging10.1007/s00259-017-3687-3201744S155-66Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developmentsKatja Pinker, Christopher Riedl, Wolfgang A. Weberhttp://link.springer.com/article/10.1007/s00259-017-3687-3/fulltext.html, http://link.springer.com/content/pdf/10.1007/s00259-017-3687-3.pdf, http://link.springer.com/content/pdf/10.1007/s00259-017-3687-3.pdf
European Journal of Nuclear Medicine and Molecular Imaging10.1007/s00259-016-3420-7201643111945-1953Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancerJingjie Shang, Xueying Ling, Linyue Zhang, Yongjin Tang, Zeyu Xiao, Yong Cheng, Bin Guo, Jian Gong, Li Huang, Hao Xuhttp://link.springer.com/content/pdf/10.1007/s00259-016-3420-7.pdf, http://link.springer.com/article/10.1007/s00259-016-3420-7/fulltext.html, http://link.springer.com/content/pdf/10.1007/s00259-016-3420-7
Cancer10.1002/cncr.2625520111181147-156Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinomaJulien Edeline, Eveline Boucher, Yan Rolland, Elodie Vauléon, Marc Pracht, Christophe Perrin, Catherine Le Roux, Jean-Luc Raoulhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncr.26255
Journal of Vascular and Interventional Radiology10.1016/j.jvir.2009.12.1702010212S13Abstract No. 27: Do the RECIST Amendment for Tumor Response Evaluation criteria correlate better with patient outcomes than the RECIST 1.1 criteria after conventional transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC)?P. Kranokpiraksa, J.R. Kachura, R. Beecroft, K. Tan, D.K. Rajan, J.D. Jaskolkahttps://api.elsevier.com/content/article/PII:S1051044309013207?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1051044309013207?httpAccept=text/plain
Yearbook of Oncology10.1016/s1040-1741(08)70075-720062006108-109Should CA-125 Response Criteria Be Preferred to Response Evaluation Criteria in Solid Tumors (RECIST) for Prognostication During Second-Line Chemotherapy of Ovariarf Carcinoma?J.T. Thigpenhttps://api.elsevier.com/content/article/PII:S1040174108700757?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1040174108700757?httpAccept=text/plain
Journal of Thoracic Oncology10.1016/j.jtho.2017.09.61820171211S1875-S1876MA 17.12 Comparison of EORTC, PERCIST, PeterMac & Deauville PET Response Criteria after Radical ChemoRT in Non-Small-Cell Lung CancerG. Turgeon, A. Iravani, T. Akhurst, J. Callahan, A. Cole, M. Bressel, S. Everitt, S. Siva, D. Ball, M. Mac Manushttps://api.elsevier.com/content/article/PII:S1556086417313539?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1556086417313539?httpAccept=text/plain
European Journal of Cancer10.1016/j.ejca.2005.04.005200541101426-1430RECIST vs. WHO: Prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcomaP. Therasse, A. Le Cesne, M. Van Glabbeke, J. Verweij, I. Judsonhttps://api.elsevier.com/content/article/PII:S0959804905002765?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0959804905002765?httpAccept=text/plain
Journal of Cancer Research and Clinical Oncology10.1007/s00432-015-2022-220151421187-194Comparing RECIST with EORTC criteria in metastatic bladder cancerHakan Öztürkhttp://link.springer.com/content/pdf/10.1007/s00432-015-2022-2.pdf, http://link.springer.com/article/10.1007/s00432-015-2022-2/fulltext.html, http://link.springer.com/content/pdf/10.1007/s00432-015-2022-2